Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis
Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to evaluate the safety and efficacy of NC-503 compared to
placebo in patients with secondary (AA) amyloidosis using a composite assessment of clinical
improvement/worsening of both renal and gastrointestinal functions.